Compare Merck & Co., Inc. (MRK) vs ProShares Ultra Gold ETF (UGL) Price & Performance

Merck & Co., Inc.Trade

ProShares Ultra Gold ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs ProShares Ultra Gold ETF — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while ProShares Ultra Gold ETF trades at $44.96. The key difference: Merck & Co., Inc. pays a 2.73% dividend while ProShares Ultra Gold ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.

	MRK	UGL
Market Cap	$307.25B	—
Sector	Health	Leveraged / Inverse
52-Week High	$129.52	$85.62
52-Week Low	$77.60	$33.59
Enterprise Value	$350.66B	—
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

ProShares Ultra Gold ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 4 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 1 day agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

UGL

ProShares Ultra Gold and UltraShort Gold offer opposite 2x gold exposure but suit different tactical bets.24/7 Wall Street · 3 days agoNeutral Leveraged gold ETFs like UGL and GLL suffer significant decay in volatile markets, reducing expected returns.24/7 Wall Street · 4 days agoBearish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About ProShares Ultra Gold ETF

UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.